ClinicalTrials.gg
CompletedNCT02496000Updated Nov 13, 2019Results posted

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

A Phase 2 interventional study of ORMD-0801 and Placebo Comparator in Diabetes Type 2, sponsored by Oramed, Ltd.. Completed at 34 sites in United States. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
1,043rd of 2,957
188 · median 90
Started
2015
with 114 others
Phase 2
391 of 3,304
24 open now
Registered
1,726th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,043rd largest by enrollment of the 2,957 interventional ones that give a count, is one of 115 that started in 2015, is one of 391 in phase 2, and was the 1,726th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

Randomized, double-blind, placebo-controlled, parallel group study.

Read the detailed description

This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel group study. After appropriate screening, approximately 180 male and female patients from up to 33 study centers will be treated in this study. Patients with type 2 diabetes mellitus who are being treated by diet, exercise, untreated with antidiabetic medications or treated with and metformin monotherapy or in combination with one other antidiabetic drug (excluding insulin) are eligible for enrollment.

03

Conditions studied

  • Diabetes Type 2

Keywords

  • Diabetes Mellitus type 2
  • Metformin
  • oral insulin
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥7.5% if naïve to antidiabetic therapy; ≥6.5% and ≤10% if on metformin ≥1,500 mg daily; ≥6.5% and ≤9.5% if on monotherapy with an antidiabetic drug other than metformin; ≥ 6.5% and ≤9.5% if on metformin and one other antidiabetic drug; ≥ 7.0% if on metformin \<1,500 mg daily.
  • At time of randomization, patients will be treated for their diabetes by diet, exercise, and metformin (≥1500 mg/day; any type and regimen). Patients will have been on a stable regimen of metformin (defined as the same metformin dose and type) for at least two weeks prior to entering the single-blind placebo run-in period.
  • Other antidiabetic agents will not be used for the two weeks prior to entering the placebo run-in period.
  • Patients in whom the maximum tolerated dose (MTD) of metformin is 1,000 mg will be allowed to enter the study.
  • At Day -7 (Visit 3), all patients will have HbA1c ≥ 6.5% and ≤10%.
  • between 25 and 40 kg/m2, inclusive.
  • Fasting blood glucose ≥ 126 mg/dL (8.3 mmol/L) prior to randomization at Day -7 (Visit 3). For patients in whom the Day -7 (Visit 3) fasting blood glucose is \<126 mg/dL and ≥ 115 mg/dL, and the Day -7 (Visit 3) HbA1C is ≥ 7% and ≤ 10%, a minimum of 5 daily self- monitored fasting blood glucose checks recorded in the patient diary can be averaged. If the average value is ≥ 126 mg/dL, the patient may continue in the trial.
  • Females of must have a negative urine pregnancy test result at screening. A negative urine pregnancy test must be obtained during Visit 2 and at Visit 4 (prior to randomization).
  • Males and females of childbearing potential must use two methods of (double barrier method), one of which must be an acceptable barrier method from the time of screening to the last study visit (Day 43).
  • Patient has >80% compliance with placebo during run in prior to randomization.
  • Patient has ≥ 80% of the glucose readings on at least two 24 hour periods (6AM - 6AM) during the seven day CGM period.
  • Patient has performed ≥ 10/14 of the self monitored glucose level measurements during placebo run-in, prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any of the following criteria are not eligible for this study.
  • Presence of any endocrine disease according to the Investigator (euthyroid patients on replacement therapy will be included if the dosage of thyroxine is stable for at least six weeks prior to Screening Visit).
  • Clinical diagnosis of Type 1 diabetes.
  • Fasting blood glucose >260 mg/dL at the end of Day -7/Visit 3. For patient in whom the Day 07 (Visit 3) fasting blood glucose is > 260 mg/dL and \< 300 mg/dL, and the Day -7 (Visit 3) is ≥ 7% and ≤ 10%, a minimum of 5 self-monitored fasting blood glucose checks recorded in the patient diary can be averaged. If the average value is ≤ 260 mg/dL, the patient may continue in the trial.
  • Presence or history of cancer within the past five years with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer.
  • Laboratory abnormalities at screening including:

    1. C-peptide \< 1.0 ng/mL.
    2. Positive pregnancy test in females of (at screening and start of run-in period).
    3. Abnormal serum thyrotropin (TSH) levels >1.5 times the .
    4. Positive test for surface antigen and/or antibody.
    5. Positive test for .
    6. Serum Cr >1.4mg/dl in males, >1.3mg/dl in females.
    7. Any relevant abnormality interfering with the efficacy or the safety assessments during study drug administration.
  • Use of the following medications:

    1. History of use of insulin for greater than one week in the last six months and any use of insulin in the last six weeks prior to randomization.
    2. Administration of anti-diabetic drugs other than metformin within four weeks prior to randomization visit. Administration of thyroid preparations or thyroxine within six weeks prior to screening visit. (Patients on stable thyroid replacement therapy for greater than 6 weeks may enter the study.)
  • Administration of systemic long-acting within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids within 30 days prior to screening visit.
  • Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled steroids (as discussed above), beta blockers (with the exception of beta blocker ophthalmic solutions for glaucoma or ocular hypertension), and or immunomodulating agents.
  • History of tobacco or nicotine use in excess of two packs/day within ten weeks prior to screening.
  • Patient is on a weight loss program and is not in the maintenance phase, or patient that started any approved or non approved weight loss medication within eight weeks prior to screening.
  • Pregnancy or breast-feeding.
  • Patient has a screening visit systolic blood pressure of ≥160 mm Hg or diastolic blood pressure of ≥100 mm Hg Patients will be allowed to take BP medication as long as they have been on a stable dose for a period of four weeks prior to the screening visit.
  • Patient is, at the time of signing , a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking).
  • Elevated liver enzymes ( (ALT), alanine aminotransferase (AST), alkaline phosphatase) greater than two times the upper limit of normal at screening.
  • Very high triglyceride level (>500 mg/dL) at screening.
  • Any clinically significant (ECG) abnormality at screening or cardiovascular disease. Clinically significant cardiovascular disease will include:

    1. History of stroke, , or myocardial infarction within six months prior to screening,
    2. History of or currently have New York Heart Associate Class II-IV heart failure prior to screening, or
    3. Uncontrolled hypertension defined as blood pressure ≥160 mmHg (systolic) or ≥100 mmHg (diastolic) at screening.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Placebo comparator
    Placebo Comparator

    three identical capsules containing placebo

    Drug: Placebo Comparator

  • Experimental
    ORMD-0801 Dose 1

    three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo

    Drug: ORMD-0801

  • Experimental
    ORMD-0801 Dose 2 = 1.5 * Dose 1

    three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1

    Drug: ORMD-0801

Interventions

  • Oral Insulin

    Also known as: Oral Insulin

  • DrugPlacebo Comparator

    Placebo

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.

    The Effect of ORMD-0801 (Doses 1 \& 2, Pooled) on Mean Night Time Glucose Levels (measured in mg/dL) Based on 2 Nights of Continuous Glucose Monitor (CGM) Data by Comparison of the Mean Change Between Baseline and Wk 4 of ORMD-0801 Treatment and Placebo Groups. The primary analysis will be based on the results from the two last days, unless technical difficulties preclude calculation of the weighted mean glucose levels. In this case, the last two days (selected between days 5, 6, and 7) with at least 80% of the expected number of measurements will be used. If days 5, 6 and 7 do not have 2 days with at least 80% of the expected number of measurements for a specific subject, then the value will be missing for that subject.

    Time frame: Baseline-Study day -7 (± 1 day) through Study day 1 (± 1 day), and Week 4 -Study day 22 (± 1 day) through Study day 29 (± 1 day)

Secondary outcomes

  1. The Effect of ORMD-0801 on Mean 24-hour Glucose

    The effect of ORMD-0801 (Dose 1 and Dose 2 individually) on mean 24-hour glucose based on 2 nights of CGM data by comparison of the mean percent change between baseline and Wk 4 of ORMD-0801 treatment and the placebo groups.

    Time frame: Study day -7 (± 1 day) through Study day 1 (± 1 day), and Study day 22 (±1 day) - Study day 29 (± 1 day)

  2. Measure Percent Change in Continuous Glucose Monitoring Mean Fasting Glucose Between Treatment and Run-In

    The percent change in the Continuous Glucose Monitoring Mean Fasting Glucose between treatment and mean of the last two days of the baseline(run-in period).

    Time frame: Baseline (Run-in days 13-14) and Study day 1 (± 1 day) through Study day 29 (± 1 day)

  3. Measure the Change From Baseline to End of the Study of Morning Fasting C-Peptide (Nmol/L)

    The measurement of the change in Morning Fasting C-peptide between baseline to end of the study, measured in Nmol/L

    Time frame: Study day 1 (±1 day) through Study day43 (± 1 day)

  4. The Effect of ORMD-0801 on the Percent Change in HbA1c

    The effect of ORMD-0801 (Dose 1 and Dose 2 individually) on the percent change from baseline to Wk 4 in HbA1c

    Time frame: Study day 1 (± 1 day) through Study day 29 (± 1 day)

07

Results

Posted Feb 17, 2017

Participant flow

Participant flow — Overall Study
MilestonePlacebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1
Started646163
Completed625661
Not completed252
Withdrew: Withdrawal by subject120
Withdrew: Lost to follow-up101
Withdrew: Protocol violation001
Withdrew: Non-compliance or lack of cooperation020
Withdrew: Undetermined010

Outcome measures

PrimaryMeasure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.

The Effect of ORMD-0801 (Doses 1 \& 2, Pooled) on Mean Night Time Glucose Levels (measured in mg/dL) Based on 2 Nights of Continuous Glucose Monitor (CGM) Data by Comparison of the Mean Change Between Baseline and Wk 4 of ORMD-0801 Treatment and Placebo Groups. The primary analysis will be based on the results from the two last days, unless technical difficulties preclude calculation of the weighted mean glucose levels. In this case, the last two days (selected between days 5, 6, and 7) with at least 80% of the expected number of measurements will be used. If days 5, 6 and 7 do not have 2 days with at least 80% of the expected number of measurements for a specific subject, then the value will be missing for that subject.

Time frame:
Baseline-Study day -7 (± 1 day) through Study day 1 (± 1 day), and Week 4 -Study day 22 (± 1 day) through Study day 29 (± 1 day)
Reported as:
Mean · mg/dL
Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.
mg/dLPlacebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1ORMD-0801 Doses 1 and 2 Combined
Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.13.70 ± 26.140-3.67 ± 18.9836.64 ± 26.3611.66 ± 23.541
Statistical analysis
  • Placebo Comparator vs ORMD-0801 Dose 1 vs ORMD-0801 Dose 2 = 1.5 * Dose 1 · Kruskal-Wallis · p = 0.0117ANOVA model on the ranks
SecondaryThe Effect of ORMD-0801 on Mean 24-hour Glucose

The effect of ORMD-0801 (Dose 1 and Dose 2 individually) on mean 24-hour glucose based on 2 nights of CGM data by comparison of the mean percent change between baseline and Wk 4 of ORMD-0801 treatment and the placebo groups.

Time frame:
Study day -7 (± 1 day) through Study day 1 (± 1 day), and Study day 22 (±1 day) - Study day 29 (± 1 day)
Reported as:
Mean · percent change
The Effect of ORMD-0801 on Mean 24-hour Glucose
percent changePlacebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1
The Effect of ORMD-0801 on Mean 24-hour Glucose5.34 ± 13.8813.33 ± 21.4991.93 ± 19.795
SecondaryMeasure Percent Change in Continuous Glucose Monitoring Mean Fasting Glucose Between Treatment and Run-In

The percent change in the Continuous Glucose Monitoring Mean Fasting Glucose between treatment and mean of the last two days of the baseline(run-in period).

Time frame:
Baseline (Run-in days 13-14) and Study day 1 (± 1 day) through Study day 29 (± 1 day)
Reported as:
Mean · percent change
Measure Percent Change in Continuous Glucose Monitoring Mean Fasting Glucose Between Treatment and Run-In
percent changePlacebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1
Measure Percent Change in Continuous Glucose Monitoring Mean Fasting Glucose Between Treatment and Run-In12.76 ± 23.2454.54 ± 24.1533.28 ± 27.331
SecondaryMeasure the Change From Baseline to End of the Study of Morning Fasting C-Peptide (Nmol/L)

The measurement of the change in Morning Fasting C-peptide between baseline to end of the study, measured in Nmol/L

Time frame:
Study day 1 (±1 day) through Study day43 (± 1 day)
Reported as:
Mean · Nmol/L
Measure the Change From Baseline to End of the Study of Morning Fasting C-Peptide (Nmol/L)
Nmol/LPlacebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1
Measure the Change From Baseline to End of the Study of Morning Fasting C-Peptide (Nmol/L)0.08 ± 0.2520.03 ± 0.4760.7 ± 0.300
SecondaryThe Effect of ORMD-0801 on the Percent Change in HbA1c

The effect of ORMD-0801 (Dose 1 and Dose 2 individually) on the percent change from baseline to Wk 4 in HbA1c

Time frame:
Study day 1 (± 1 day) through Study day 29 (± 1 day)
Reported as:
Mean · percent change
The Effect of ORMD-0801 on the Percent Change in HbA1c
percent changePlacebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1
The Effect of ORMD-0801 on the Percent Change in HbA1c0.2 ± 0.4970.00 ± 0.544-.03 ± 0.554

Adverse events

Collected over eight (8) months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Comparator—0/64 (0%)0/64 (0%)
ORMD-0801 Dose 1—1/61 (1.6%)0/61 (0%)
ORMD-0801 Dose 2 = 1.5 * Dose 1—0/63 (0%)0/63 (0%)
Most frequent serious events
Most frequent serious events
EventPlacebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1
Serious Non-Treatment Emergent Adverse EventNervous system disorders0/641/610/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1Total
Mean58.61 ± 9.20357.89 ± 8.02157.25 ± 8.78657.92 ± 8.69
Sex: Female, Male
Sex: Female, Male(Participants)Placebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1Total
Female35222986
Male293934102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1Total
Hispanic or Latino31323699
Not Hispanic or Latino33292789
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo ComparatorORMD-0801 Dose 1ORMD-0801 Dose 2 = 1.5 * Dose 1Total
American Indian or Alaska Native0000
Asian2226
Native Hawaiian or Other Pacific Islander2103
Black or African American78419
White535055158
More than one race0000
Unknown or Not Reported0022
08

Study locations

34 sites
  • Steingard Medical Group
    Phoenix, Arizona 85015, United States
  • Arkansas Primary Care Clinic, PA
    Little Rock, Arkansas 72204, United States
  • Dream Team Clinical Research
    Anaheim, California 92801, United States
  • ACTCA, Inc.
    Los Angeles, California 90017, United States
  • ACTCA
    Los Angeles, California 90036, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Mills-Peninsula Health Services
    San Mateo, California 94401, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Creekside Endocrine Associates, PC
    Denver, Colorado 80209, United States
  • Meridien Research
    Bradenton, Florida 34208, United States
  • Meridien Research
    Brooksville, Florida 34601, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Research in Miami Inc.
    Hialeah, Florida 33013, United States
  • Research in Miami, Inc.
    Hialeah, Florida 33013, United States
  • Phoenix Medical Research LLC
    Miami, Florida 33165, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Metabolic Research Institute, Inc
    West Palm Beach, Florida 33401, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Maine Research Associates
    Auburn, Maine 04210, United States
  • Apex Medical Research, MI, Inc
    Flint, Michigan 48504, United States
  • Impact Clinical Trials
    Las Vegas, Nevada 89106, United States
  • New York Clinical Trials
    New York, New York 10018, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73069, United States
  • Upstate Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Padre Coast Clinical Research
    Corpus Christi, Texas 78404, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Southwest Clinic
    San Antonio, Texas 78221, United States
  • Panacea Clinical Research
    San Antonio, Texas 78228, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Wasatch Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
  • Rainier Clinical Research Center, Inc.
    Renton, Washington 98057, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jun 2016, 11 months.

Results were first posted in Feb 2017, 7 months after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2015
First posted
Jul 14, 2015
StartActual
Jul 27, 2015
Primary completionActual
Jun 27, 2016
CompletionActual
Sep 13, 2016
Results first posted
Feb 17, 2017
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02496000
Lead sponsor
Oramed, Ltd.
Collaborators
Integrium
Responsible party
Sponsor
First posted
Jul 14, 2015
Start date
Jul 27, 2015
Primary completion
Jun 27, 2016
Completion
Sep 13, 2016
Results posted
Feb 17, 2017
Last update
Nov 13, 2019

Study contacts

Joel M Neutel, M.D.
principal investigator · Orange County Research Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ORMD-0801

Start the discussion